Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(11):885-887; doi:10.1093/jnci/djh171
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jankowski, J.
Right arrow Articles by Moayyedi, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jankowski, J.
Right arrow Articles by Moayyedi, P.
Related Collections
Right arrowRelated Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

CORRESPONDENCE

Re: Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus

Janusz Jankowski, Paul Moayyedi

Affiliations of authors: Digestive Diseases Centre, Departments of Genetics and Molecular Medicine, University of Leicester, Leicester, UK (JJ); GI Unit, McMaster University, Hamilton, Ontario, Canada (PM)

Correspondence to: J. A. Z. Jankowski, MD, PhD, FRCP, Level 4, Windsor Building, Departments of Genetics and Molecular Medicine, Medical School and University Hospitals Trust, Royal Infirmary, LE1 5WW, Leicester, UK (e-mail: j.jankowski@le.ac.uk)

The first 10% of the full text of this article appears below.

We write in regard to the article by Hur et al. (1) that appeared in the Journal. This article highlighted the value of aspirin for chemoprevention of Barrett's esophagus. We believe that this article is extremely timely. We are now addressing this same point in one of the largest randomized controlled trials in clinical gastroenterology that will involve 5000 male patients aged between 40 and 75 years with long-segment Barrett's metaplasia of the esophagus and have a 2-by-2 intervention trial factorial design (Fig. 1). This trial has been reviewed and funded by external grant authorities in the United Kingdom (namely Cancer Research . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Correspondence

RESPONSE: Re: Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus
Chin Hur, Norman Nishioka, and G. Scott Gazelle
J Natl Cancer Inst 2004 96: 887. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Therapeutic Advances in GastroenterologyHome page
T. C. Wang and G. Mallarkey
Editorial: What are the therapeutic advances in gastroenterology? Opinions from world experts
Therapeutic Advances in Gastroenterology, September 1, 2008; 1(2): 85 - 90.
[PDF]

Home page
 Therapeutic Advances in GastroenterologyHome page
J. A. Abrams
Review: Chemoprevention of esophageal adenocarcinoma
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 7 - 18.
[Abstract] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. B. Cook, C. P. Wild, S. M. Everett, L. J. Hardie, K. E. Bani-Hani, I. G. Martin, and D. Forman
Risk of Mortality and Cancer Incidence in Barrett's Esophagus
Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2090 - 2096.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
E. Zagorowicz and J. Jankowski
Molecular changes in the progression of Barrett's oesophagus
Postgrad. Med. J., August 1, 2007; 83(982): 529 - 535.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S L Preston and J A Jankowski
Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full!
Gut, October 1, 2006; 55(10): 1377 - 1379.
[Full Text] [PDF]

Home page
 BMJHome page
J. Jankowski and H. Barr
Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base.
BMJ, June 24, 2006; 332(7556): 1512 - 1512.
[Full Text]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
K. J. Smith, S. M. O'Brien, B. M. Smithers, D. C. Gotley, P. M. Webb, A. C. Green, D. C. Whiteman, and for the Study of Digestive Health
Interactions among Smoking, Obesity, and Symptoms of Acid Reflux in Barrett's Esophagus
Cancer Epidemiol. Biomarkers Prev., November 1, 2005; 14(11): 2481 - 2486.
[Abstract] [Full Text] [PDF]